Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying cancer patients at risk for cardiotoxicity.

Future oncology (London, England) - 1 Jan 2015

Salvatici Michela, Sandri Maria T

Abstract excerpt

Improvements in therapies have significantly changed survival of cancer patients. However, the clinical history and oncologic treatment put cancer patients at higher risk for developing cardiovascular problems. Anthracyclines, but also the targeted therapy and angiogenesis inhibitors, are all treatments associated with cardiotoxicity. The most common adverse event is a reduction in left ventricular ejection...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Galectins
Share to Antineoplastic Agents
Share to Blood Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiotoxicity

Share to Galectin 3

Share to Precision Medicine

Share to Troponin T

Share to Ventricular Dysfunction, Left

Source

Identifiers

PMID: 26198838
DOI: 10.2217/fon.15.69

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying cancer patients at risk for cardiotoxicity.PMID 26198838Read ↗

Heart Failure in Relation to Anthracyclines and Other Chemotherapies.Semantic proximity Read ↗

Epigenetic Changes Associated With Anthracycline‐Induced CardiotoxicitySemantic proximity Read ↗

Pathophysiology of anthracycline cardiotoxicity.Semantic proximity Read ↗

Current views on anthracycline cardiotoxicity.Semantic proximity Read ↗

Prognostic Factors for Cardiotoxicity Among Children With Cancer: Definition, Causes and Diagnosis With Omics TechnologiesSemantic proximity Read ↗

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Semantic proximity Read ↗

Prevalence and Effects of Late Cardiotoxicity induced by Anthracyclines and/or Anti- HER2 Antibodies in Patients with Breast Cancer: a real world studySemantic proximity Read ↗

Anthracycline-mediated cardiomyopathy: Basic molecular knowledge for the cardiologistSemantic proximity Read ↗

Personalized medicine in cardio-oncology: the role of induced pluripotent stem cellSemantic proximity Read ↗

Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profilingSemantic proximity Read ↗

Genetic factors in the pathogenesis of cardio-oncology.Semantic proximity Read ↗

Circulating MicroRNA as Biomarkers of Anthracycline-Induced CardiotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.